ARGENT BIOPHARMA LIMITEDARGENT BIOPHARMA LIMITEDARGENT BIOPHARMA LIMITED

ARGENT BIOPHARMA LIMITED

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪13.03 M‬AUD
−0.535AUD
‪−17.53 M‬AUD
‪891.08 K‬AUD
‪47.96 M‬
Beta (1Y)
−1.51

About ARGENT BIOPHARMA LIMITED


CEO
Roby Reuven Zomer
Headquarters
Subiaco
Founded
2005
ISIN
AU0000326647
FIGI
BBG000QCLWF4
Argent BioPharma Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Roby Zomer on October 21, 2005 and is headquartered in Perth, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RGT is 0.250 AUD — it has increased by 4.17% in the past 24 hours. Watch ARGENT BIOPHARMA LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange ARGENT BIOPHARMA LIMITED stocks are traded under the ticker RGT.
RGT stock has fallen by −3.85% compared to the previous week, the month change is a −16.67% fall, over the last year ARGENT BIOPHARMA LIMITED has showed a −63.77% decrease.
RGT reached its all-time high on Feb 19, 2021 with the price of 130.000 AUD, and its all-time low was 0.150 AUD and was reached on Aug 15, 2024. View more price dynamics on RGT chart.
See other stocks reaching their highest and lowest prices.
RGT stock is 4.00% volatile and has beta coefficient of −1.51. Track ARGENT BIOPHARMA LIMITED stock price on the chart and check out the list of the most volatile stocks — is ARGENT BIOPHARMA LIMITED there?
Today ARGENT BIOPHARMA LIMITED has the market capitalization of ‪13.03 M‬, it has decreased by −19.30% over the last week.
Yes, you can track ARGENT BIOPHARMA LIMITED financials in yearly and quarterly reports right on TradingView.
ARGENT BIOPHARMA LIMITED is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
RGT net income for the last half-year is ‪−10.45 M‬ AUD, while the previous report showed ‪−7.08 M‬ AUD of net income which accounts for −47.73% change. Track more ARGENT BIOPHARMA LIMITED financial stats to get the full picture.
No, RGT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARGENT BIOPHARMA LIMITED EBITDA is ‪−16.38 M‬ AUD, and current EBITDA margin is ‪−1.90 K‬%. See more stats in ARGENT BIOPHARMA LIMITED financial statements.
Like other stocks, RGT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARGENT BIOPHARMA LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARGENT BIOPHARMA LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARGENT BIOPHARMA LIMITED stock shows the sell signal. See more of ARGENT BIOPHARMA LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.